Objectives: This observational study analyzed telomerase reverse transcriptase (pTERT) mutations in 45 fine-needle aspiration (FNA) specimens obtained from thyroid nodules followed by postoperatively confirmation of papillary thyroid cancer (PTC) diagnosis, examining their relationship with clinicopathologic aspects and the BRAF V600E mutation. 
INTRODUCTION
P apillary thyroid cancer (PTC) risk stratification and prognostication has been normally placed on clinicopathologic aspects, which are usually unreliable and presurgically nonexistent (1) . In recent years, molecularly established prognostication for PTC has been broadly advised (2) (3) (4) . The role of BRAF V600E -mutation test in bettering the preoperative premonition of thyroid nodules US guided fine-needle aspiration (FNA) is dubious in terms of the prognostic accuracy of BRAF V600E mutations in PTC (5, 6) . Telomerase reverse transcriptase (TERT) has been known to play a decisive role in cellular immortality by preserving the telomere length at the end of chromosomes and in encouraging other cellular functions such as proliferation and cell cycles (7) . TERT gene promoter mutations (pTERT) increment the transcriptional activities of the TERT and have been connected to malignant tumors with superlative recurrence and lower survival in PTC (7, 8) . Only three studies preoperatively investigated pTERT mutations in PTC patients and proposed that the awareness of the mutation status might guide the amplitude of initial surgery (9) (10) (11) . Coexistence of BRAF V600E and pTERT mutations leads to a more aggressive subgroup of PTC, whereas the two mutations alone have relatively less impact on the aggressiveness of PTC (12) . This study preoperatively scrutinized high-risk thyroid nodules confirmed as PTC tumors for pTERT mutations and inspected their relationship with clinicopathologic features at the moment of the diagnosis and cooccurrence with the BRAF V600E -mutation.
SUBJECTS AND METHODS

FNA specimens
We have studied 59 consecutive patients with highrisk thyroid nodules after US evaluation, followed up at the Thyroid Outpatient Clinic of the Division of Endocrinology of the Ribeirao Preto Medical School of University of São Paulo, Brazil, who needed another FNA examination and were chosen in our hospital from January 2010 to October 2012. Inclusion criteria were: (1) TIRADS 4-6 at US, or (2) TIRADS 3 that meet at least one of the following criteria: the nodule grows during follow-up (more than a 50% change in volume or a 20% increase in at least two nodule dimensions with a minimal increase of 2 mm in solid nodules or in the solid portion of mixed cystic-solid nodules), patients with higher risk of malignancy like those exposed to previous radiation to the neck or family history of DTC, and (3) histologic confirmation of PTC after thyroidectomy and elective lymph node dissection. TNM classification was built according to the American Joint Committee on Cancer (AJCC) 8 th edition (13, 14) . Genomic DNA from FNA specimens preoperatively obtained was isolated, and nested PCR was performed for direct genomic DNA sequencing to identify both the C228T and C250T pTERT mutations as previously described (9) (10) (11) .
FNA biopsy used 24-gauge needles fitted to a 10-mL syringe. Most of the material (about two thirds) from the needle was used for cytological examination, and the remaining amount was used for DNA isolation after needle washing with 1 mL of the phosphate buffer. Then the sample was stored and frozen for future DNA extraction, using 20-50 μL of DNA extraction buffer solution (50 mM Tris buffer, pH 8.3; 1 mM EDTA, pH 8.0; 5% Tween 20 and 100 μg/mL proteinase K) with 10% resin added to the samples and incubated at 56.8 °C for a minimum of 1 hour. After incubation, the tubes were heated to 100 °C for 10 minutes, followed by centrifugation to pellet the debris, and 5 μL of the supernatant was used in the PCR reaction. pTERT mutation analysis
BRAF
A fragment of the pTERT, which contained the sites for pTERT C250T and pTERT C228T mutations, was amplified by nested PCR on 50-100 ng of genomic DNA from FNA specimens. The first PCR used pair primers 
Statistic analysis
RESULTS
A total of 59 patients with confirmed PTC was enrolled, and 14 patients were excluded due PCR failure (n = 8) and 6 due to incomplete clinical data. Therefore, 45 thyroid nodules confirmed as PTC cases were included after histological re-review by two experienced pathologists. As reported in Table 1 (Figure 1 ). However, in the follow-up evaluation, one patient had died, two present excellent response and another has indeterminated response to treatment at the study data snapshot.
CONCLUSION
We investigated the feasibility of combined BRAF V600E / pTERT mutations testing on routine FNA specimens and its prognostic value in US guide biopsied of high suspicious thyroid nodules. The BRAF V600E and pTERT mutations were found in a frequency of 66.7% and 8.9%, respectively. Indeed, we observed that BRAF V600E /pTERT mutation-positive thyroid nodules were detected only in cancers that behaved aggressively, representing 4/11 (36%) of advanced stage PTCs and harboring threatening clinic-pathological features such as lymph node metastases, extra-thyroidal invasion and distant metastases (Table 3) .
We did not evaluate the degree of concordance between matched FNA and formalin-fixed, paraffinembedded samples. The mutation analysis sensitivity can be compromised by using lavage fluid once the amount and composition of the cellular content is unknown, potentially leading to discordance between matched FNA and formalin-fixed, paraffin-embedded. As a result, we were not able to measure the mutation false-negative and false-positive rates on FNA preparations. Indeed, strategies such as real-time Light Cycler PCR and fluorescence melting curve analysis might be superior.
In conclusion, preoperative determination of BRAF V600E and pTERT mutations status can be easily performed on cytologic preparation using lavage fluids collected from needle rinsing. The presence of the BRAF V600E /pTERT mutations could be a marker of poor 
